Common genetic variants identify therapeutic targets for COVID-19 and

2 individuals at high risk of severe disease

- J. E. Horowitz^{1†}, J. A. Kosmicki^{1†}, A. Damask¹, D. Sharma¹, G. H. L. Roberts², A. E. Justice³, N. 4
- 5 Banerjee¹, M. V. Coignet², A. Yadav¹, J. B. Leader³, A. Marcketta¹, D. S. Park², R. Lanche¹, E.
- Maxwell¹, S. C. Knight², X. Bai¹, H. Guturu², D. Sun¹, A. Baltzell², F. S. P. Kury¹, J. D. Backman¹, 6
- 7 A. R. Girshick², C. O'Dushlaine¹, S. R. McCurdy², R. Partha², A. J. Mansfield¹, D. A. Turissini²,
- 8 A. H. Li¹, M. Zhang², J. Mbatchou¹, K. Watanabe¹, L. Gurski¹, S. E. McCarthy¹, A. Verma⁴, G.
- Sirugo⁴, Regeneron Genetics Center*, M. D. Ritchie⁴, M. Jones¹, S. Balasubramanian¹, W. J. 9
- Salerno¹, A. R. Shuldiner¹, D. J. Rader⁴, T. Mirshahi³, A. E. Locke¹, J. Marchini¹, J. D. Overton¹, 10
- D. J. Carey³, L. Habegger¹, M. N. Cantor¹, K. A. Rand², E. L. Hong², J. G. Reid¹, C. A. Ball², A. 11
- Baras^{1‡}, G. R. Abecasis^{1‡}, M. A. Ferreira^{1‡} 12
- 14 From:

13

20

25

1

- ¹Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA 15
- ²AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043, USA 16
- 17 ³Geisinger, Danville, PA, 17822, USA
- 18 ⁴Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
- 19 PA, 19104, USA
- 21 *A complete list of investigators is provided in the Supplementary Appendix.
- 22 †J. A. Kosmicki and J. E. Horowitz contributed equally to this manuscript.
- 23 [‡]A. Baras, G. R. Abecasis and M. A. Ferreira jointly supervised this work.
- 24 Correspondence to: manuel.ferreira@regeneron.com and goncalo.abecasis@regeneron.com
- 26 This research has been conducted using the UK Biobank Resource (Project 26041)

ABSTRACT

The need to identify and effectively treat COVID-19 cases at highest risk for severe disease is critical. We identified seven common genetic variants (three novel) that modulate COVID-19 susceptibility and severity, implicating *IFNAR2*, *CCHCR1*, *TCF19*, *SLC6A20* and the hyaluronan pathway as potential therapeutic targets. A high genetic burden was strongly associated with increased risk of hospitalization and severe disease among COVID-19 cases, especially among individuals with few known risk factors.

MAIN TEXT

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1] causes coronavirus disease 2019 (COVID-19)[2], which has lead to >1.5 million recorded deaths worldwide since December 2019 [3]. Reported risk factors for severe COVID-19, defined here as death or hospitalization combined with respiratory failure [4], include male sex, older age, race, obesity, kidney, cardiovascular and respiratory diseases [5-8]. Corticosteroids, repurposed anti-viral medicines, and antibody therapies have been authorized to treat COVID-19 [9-12]. Presently, excess mortality due to COVID-19 is high and the urgent need for therapies that treat or prevent severe disease remains. Further, identifying individuals at highest risk of adverse outcomes may help prioritize individuals for vaccines [13, 14] or monoclonal antibody treatments [15, 16], which are currently in short supply. In this study, we used human genetics to identify potential therapeutic targets for severe COVID-19 and developed genetic risk scores to identify individuals at highest risk of severe disease with greater precision than can be attained with clinical and demographic variables alone. We performed genetic association studies of COVID-19 outcomes across 11,356 individuals with COVID-19 and 651,047 individuals with no record of SARS-CoV-2 infection aggregated from four studies (Supplementary Table 1) and four ancestries (Admixed American, African, European and South Asian). Of the COVID-19 cases, 2,175 (19%) were hospitalized and 847 (7%) had severe disease; hospitalized patients were more likely to be older, of non-European ancestry and to have pre-existing cardiovascular and lung disease (Supplementary Table 2). Using these data, we defined two groups of COVID-19 outcomes: five phenotypes related to disease risk and two phenotypes related to disease severity among COVID-19 cases (Supplementary Table 3). For each phenotype, when >30 cases were available, we performed ancestry-specific genetic

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

analyses in each study (Supplementary Table 4) and then combined results across studies and ancestries using a fixed-effects meta-analysis. To identify genetic variants that modulate disease severity following SARS-CoV-2 infection, we first focused on replicating eight independent associations ($r^2 < 0.05$) with disease risk reported in recent GWAS that included >1,000 cases [17-20] (Supplementary Table 5); we hypothesized that some of these published risk variants could also modulate disease severity. After accounting for multiple testing, six variants had a significant (P<0.0012) and directionally consistent association with at least one of our five disease risk phenotypes (Supplementary Table 6): rs73064425 in LZTFL1 (strongest in contrast between COVID-19 hospitalized cases vs. COVID-19 negative or unknown controls; MAF=7%, OR=1.42, P=7x10⁻¹¹); rs2531743 near *SLC6A20* (COVID-19 positive vs. COVID-19 negative; MAF=42%, OR=1.06, $P=9\times10^{-4}$); rs143334143 in the MHC (COVID-19 severe vs. COVID-19 negative or unknown; MAF=7%, OR=1.36, P=6x10⁻¹ 4); rs9411378 in ABO (COVID-19 positive vs. COVID-19 negative or unknown; MAF=23%, OR=1.12, $P=6\times10^{-10}$); rs2109069 in *DPP9* (COVID-19 positive vs. COVID-19 negative or unknown; MAF=31%, OR=1.06, $P=10^{-4}$); and rs2236757 in *IFNAR2* (COVID-19 hospitalized vs. COVID-19 negative or unknown; MAF=29%, OR=1.13, $P=2\times10^{-4}$). Effect sizes were comparable across ancestries (Supplementary Table 7). Having established these variants as bona fide risk factors for COVID-19, we then asked which (if any) were also associated with severity amongst COVID-19 cases. We found that four of the six variants were significantly (P<0.05) associated with worse outcomes among infected individuals (Figure 1A). The exceptions were rs9411378 in ABO and rs2531743 near SLC6A20, which did not associate with COVID-19 severity (Figure 1B). Collectively, these results pinpoint four variants associated with worse disease outcomes,

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

including respiratory failure and death. These variants can be used to identify individuals at risk of severe COVID-19 and suggest that nearby genes may represent targets for therapeutic intervention. We next looked for novel genetic associations with severe COVID-19. Across our two severity phenotypes (hospitalized vs. non-hospitalized cases; severe vs. non-hospitalized cases), we found no new associations at $P < 5 \times 10^{-8}$ (Supplementary Figure 1), indicating that these analyses were underpowered for genome-wide discovery. To increase power, we combined results from our COVID-19 hospitalization phenotype (2,175 cases vs. 651,047 controls) with those from two published GWAS[19, 21], for a combined sample size of 5,461 hospitalized cases and 661,632 controls with no record of SARS-CoV-2 infection. In this larger analysis of disease risk, seven loci reached genome-wide significance (Figure 2), including the four highlighted by the replication analysis above (LZTFL1, MHC, DPP9 and IFNAR2) and three novel associations (Table 1): rs79833209 near *CCNG1* (5q34; MAF=2%, OR=1.54, *P*=2x10⁻⁸); rs4782327 in *ACSF3* (16q24.3; MAF=22%, OR=1.17, $P=8\times10^{-9}$); and rs12461764 in *FPR1* (19q13.41; MAF=35%, OR=1.18, $P=10^{-8}$). Consistent associations were observed across studies and ancestries for the three novel variants (Supplementary Figure 2). We then assessed the association between each novel variant and disease severity and found that for all three, the risk allele was overrepresented (P<0.05) amongst hospitalized and severe COVID-19 cases, relative to non-hospitalized cases (Figure 1C). To further study the association between the three variants and worse disease outcomes, we constructed a continuous score that combined nine different measures of severity self-reported by 4,448 COVID-19 cases from the AncestryDNA study. Lower severity scores were enriched for asymptomatic cases and lower symptom severity, while higher scores were associated with

increased symptom severity and elevated hospitalization rates (**Supplementary Figure 3**). The mean severity score was elevated for carriers of each of the three novel risk alleles (**Supplementary Table 8**). Therefore, the three putative novel susceptibility loci we identified for COVID-19 risk are also associated with increased risk of severe disease.

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

Collectively, our association analyses highlighted seven common variants (four known, three novel) associated with COVID-19 susceptibility ($P < 5 \times 10^{-8}$), as well as disease severity among cases (P<0.05). As all seven variants are either intronic or intergenic, it is not immediately clear how these variants influence gene function. To help identify gene targets and thus potential therapeutic targets for severe COVID-19, we searched for functional protein-coding variants (missense or predicted loss-of-function) in high LD ($r^2>0.95$) with each variant. We found six functional variants in three genes: two missense variants in IFNAR2, a component of the heterodimeric type-1 interferon receptor; three missense and a stop-gain variant in CCHCR1, a Pbody protein associated with cytoskeletal remodeling and mRNA turnover [22, 23], which can interact with human papillomavirus-16 [24, 25]; and a missense variant in TCF19, a transcription factor associated with hepatitis B [26, 27] (Supplementary Table 9). These data indicate that the risk variants identified in IFNAR2, CCHCR1 and TCF19 may have functional effects on these genes. Next, we asked if the sentinel risk variants co-localized $(r^2>0.95)$ with published sentinel expression quantitative trait loci (Supplementary Table 10), specifically focusing on 168 genes in cis (± 500 kb). We observed evidence for co-localization for IFNAR2, TCF19 and SLC6A20 (Supplementary Table 11). SLC6A20 encodes a proline transporter that binds the host SARS-CoV-2 receptor, angiotensin-converting enzyme 2 [28]. Our results suggest that higher SLC6A20 expression in the lung (and potentially increased viral uptake) is associated with higher risk of

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

severe disease (Supplementary Table 11). In contrast, for IFNAR2, our analysis suggests that severe COVID-19 is associated with lower expression in immune cells and lung tissue (Supplementary Table 11), consistent with the deficient interferon response observed in severe COVID-19 patients [29]. Collectively, these analyses identified four specific putative effector genes in COVID-19 risk loci (IFNAR2, CCHCR1, TCF19 and SLC6A20), though functional studies are required to confirm these predictions. Co-localization analyses did not identify any likely target genes for the three new risk variants. However, we note that two of these (rs12461764 and rs79833209) are near genes related to hyaluronan (HA), a major component of the lung extracellular matrix (Supplementary Figure 2): HAS1 (16 Kb away) and HMMR (160 Kb away), which respectively encode HA synthase 1 and a cell-surface receptor for HA. This observation is noteworthy because elevated HA (i) has been reported in the lungs of COVID-19 patients [30, 31]; and (ii) is associated with inflammation and other infections [31], including influenza [33]. Furthermore, *Hmmr*-deficient mice are protected in acute fibrotic lung injury models [34]. If confirmed, these findings would support the use of hyaluronidases in reducing accumulation of HA and preventing long-term lung damage in COVID-19 patients [35]. The second aim of this study was to determine if genetics can help identify individuals at high risk of severe disease, who may be prioritized for prophylactic or therapeutic interventions. Specifically, we focused on the four variants (in/near LZTFL1, MHC, DPP9 and IFNAR2) with confirmed association with COVID-19 susceptibility and that also modulate COVID-19 severity. Using these variants, we created a weighted genetic risk score (GRS) for individuals with COVID-

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

19 and then compared the risk of hospitalization and severe disease between those with a high GRS and all other cases, after adjusting for established risk factors (e.g. age, sex, comorbidities). When considering COVID-19 cases of European ancestry (N=9,277), we found that having a high GRS (top 10%) was associated with a 2.0-fold increased risk of hospitalization (95% CI 1.66-2.55, P=3x10⁻¹¹; Supplementary Figure 4A) and 1.8-fold increased risk of severe disease (95% CI 1.40-2.41, $P=10^{-5}$; Figure 3A). A consistent pattern was observed in other ancestries, though sample sizes were considerably smaller (Supplementary Tables 12 and 13). Lastly, we compared the effect of the GRS between individuals with and without established risk factors for severe COVID-19. We found that a high GRS (top 10%) was strongly associated with risk of severe disease among individuals with one (OR=3.26, 95% CI 2.03-5.23, $P=10^{-6}$) or two (OR=2.19, 95% CI 1.29-3.72, P=0.004) established risk factors (Figure 3B and 3C; Supplementary Table 14). In contrast, there was a much weaker association between a high GRS and risk of severe disease among individuals with many (three or more) risk factors (OR=1.26, 95% CI 0.75-2.11, P=0.388), although evidence for heterogeneity of GRS effect with number of risk factors was not significant (P=0.16). Similar results were observed for risk of hospitalization (Supplementary Figure 4B) and 4C; Supplementary Table 14). Collectively, these results demonstrate that a GRS calculated using variants associated with disease risk and severity can be used to identify COVID-19 cases at high risk of developing poor disease outcomes. This is important as many of these individuals might not be prioritized for prophylactic or therapeutic interventions according to current guidelines[35]. In summary, we confirmed four common variant associations with COVID-19 susceptibility and further show that they modulate disease severity and are likely to influence the function of IFNAR2, CCHCR1, TCF19 and SLC6A20. We also identified three novel associations with disease severity, which potentially provide genetic evidence for a role of hyaluronan in severe COVID-19. Lastly, we show that a genetic risk score based on the four common variants that we validated can be used to identify individuals at high risk of poor disease outcomes. Collectively, our analyses point to potential novel therapies and help identify patients at high risk of severe COVID-19.

ONLINE METHODS

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Participating Studies

AncestryDNA COVID-19 Research Study. AncestryDNA customers over age 18, living in the United States, and who had consented to research, were invited to complete a survey assessing COVID-19 outcomes and other demographic information. These included SARS-CoV-2 swab and antibody test results, COVID-19 symptoms and severity, brief medical history, household and occupational exposure to SARS-CoV-2, and blood type. A total of 83,930 AncestryDNA survey respondents were selected for inclusion in this study [36, 37]. Respondents selected for this study included all individuals with a positive COVID-19 test together with age and sex matched controls. DNA samples were genotyped as described previously[36]. Genotype data for variants not included in the array were then inferred using imputation to the Haplotype Reference Consortium (HRC) reference panel. Briefly, samples were imputed to HRC version 1.1, which consists of 27,165 total individuals and 36 million variants. The HRC reference panel does not include indels; consequently, indels are not present in the imputed data. We determined best-guess haplotypes with Eagle version 2.4.1 and performed imputation with Minimac4 version 1.0.1. We used 1,117,080 unique variants as input and 8,049,082 imputed variants were retained in the final data set. Variants with a Minimac4 R²<0.30 were filtered from the analysis. For this study, an additional continuous severity phenotype was defined for a semi-overlapping set of in 4,448 surveyrespondents that reported a positive COVID-19 test. The continuous severity score was derived by computing the first principal component across nine survey fields related to COVID-19 clinical outcomes. Six of the nine questions were binary: hospitalization, ICU admittance with oxygen, ICU admittance with ventilation, septic shock, respiratory failure, and organ failure due to COVID-19. Binary responses were encoded as 0 for "No" and 1 for "Yes". Three symptom

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

questions related to shortness of breath, fever, and nausea/vomiting symptoms were encoded as a unit-scaled variable based on the following mapping: 0="None", 0.2="Very mild", 0.4="Mild", 0.6="Moderate", 0.8="Severe", and 1.0="Very Severe". The three symptoms were chosen based on prior literature indicating their positive association with COVID-19 hospitalization[37]. The resulting score was standardized prior to association analysis. Geisinger Health System (GHS). The GHS MyCode Community Health Initiative is a health system-based cohort from central and eastern Pennsylvania (USA) with ongoing recruitment since 2006. A subset of 144,182 MyCode participants sequenced as part of the GHS-Regeneron Genetics Center DiscovEHR partnership were included in this study. Information on COVID-19 outcomes were obtained through GHS's COVID-19 registry. Patients were identified as eligible for the registry based on relevant lab results and ICD-10 diagnosis codes; patient charts were then reviewed to confirm COVID-19 diagnoses. The registry contains data on outcomes, comorbidities, medications, supplemental oxygen use, and ICU admissions. DNA from participants was genotyped on either the Illumina OmniExpress Exome (OMNI) or Global Screening Array (GSA) and imputed to the TOPMed reference panel (stratified by array) using the TOPMed Imputation Server. Prior to imputation, we retained variants that had a MAF \geq 0.1%, missingness \leq 1% and HWE p-value $> 10^{-15}$. Following imputation, data from the OMNI and GSA datasets were merged for subsequent association analyses, which included an OMNI/GSA batch covariate, in addition to other covariates described below.

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Penn Medicine BioBank (PMBB) study. PMBB study participants are recruited through the University of Pennsylvania Health System, which enrolls participants during hospital or clinic visits. Participants donate blood or tissue and allow access to EHR information[38]. The PMBB COVID-19 registry consists of patients who have positive qPCR testing for SARS-COV-2. We then used electronic health records to classify COVID-19 patients into hospitalized and severe (ventilation or death) categories. DNA genotyping was performed with the Illumina Global Screening Array, and imputation performed using the TOPMed reference panel as described for GHS above. UK Biobank (UKB) study. We studied the host genetics of SARS-CoV-2 infection in participants of the UK Biobank study, which took place between 2006 and 2010 and includes approximately 500,000 adults aged 40-69 at recruitment. In collaboration with UK health authorities, the UK Biobank has made available regular updates on COVID-19 status for all participants, including results from four main data types: qPCR test for SARS-CoV-2, anonymized electronic health records, primary care and death registry data. We report results based on the 12 September 2020 data refresh and excluded from the analysis 28,547 individuals with a death registry event prior to 2020. DNA samples were genotyped as described previously [39] using the Applied Biosystems UK BiLEVE Axiom Array (N=49,950) or the closely related Applied Biosystems UK Biobank Axiom Array (N=438,427). Genotype data for variants not included in the arrays were inferred using three reference panels (Haplotype Reference Consortium, UK10K and 1000 Genomes Project phase 3) as described previously [39].

COVID-19 phenotypes used for genetic association analyses

We grouped participants from each study into three broad COVID-19 disease categories (Supplementary Table 1): (i) positive – those with a positive qPCR or serology test for SARS-CoV-2, or a COVID-19-related ICD10 code (U07), hospitalization or death; (ii) negative – those with only negative qPCR or serology test results for SARS-CoV-2 and no COVID-19-related ICD10 code (U07), hospitalization or death; and (iii) unknown – those with no qPCR or serology test results and no COVID-19-related ICD10 code (U07), hospitalization or death. We then used these broad COVID-19 disease categories, in addition to hospitalization and disease severity information, to create seven COVID-19-related phenotypes for genetic association analyses, as detailed in Supplementary Table 3. For association analysis in the AncestryDNA study, we excluded from the COVID-19 unknown group individuals who had (i) a first-degree relative who was COVID-19 positive; or (ii) flu-like symptoms.

Genetic association analyses

Association analyses in each study were performed using the genomewide Firth logistic regression test implemented in REGENIE [40]. In this implementation, Firth's approach is applied when the p-value from standard logistic regression score test is below 0.05. We included in step 1 of REGENIE (*i.e.* prediction of individual trait values based on the genetic data) directly genotyped variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-Weinberg equilibrium test P-value>10⁻¹⁵ and linkage-disequilibrium (LD) pruning (1000 variant windows, 100 variant sliding windows and r^2 <0.9). The association model used in step 2 of REGENIE included as covariates age, age², sex, age-by-sex, and the first 10 ancestry-informative principal components (PCs) derived from the analysis of a stricter set of LD-pruned (50 variant windows, 5

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

variant sliding windows and $r^2 < 0.5$) common variants from the array (imputed for the GHS study) data. Within each study, association analyses were performed separately for four different ancestries defined based on the array data (African [AFR], admixed American [AMR], European [EUR] and South Asian [SAS]). We retained association results for variants with an imputation information score ≥ 0.3 and MAC ≥ 5 , and either (i) MAF>0.5% or (ii) a protein-altering consequence (i.e. pLOF, missense or splice variants). Results were subsequently meta-analyzed across studies and ancestries using an inverse variance-weighed fixed-effects meta-analysis. Identification of putative targets of GWAS variants based on colocalization with eQTL We identified as a likely target of a sentinel GWAS variant any gene for which a sentinel expression quantitative trait locus (eQTL) co-localized (i.e. had LD $r^2 > 0.95$) with the sentinel GWAS variant. That is, we only considered genes for which there was strong LD between a sentinel GWAS variant and a sentinel eQTL, which reduces the chance of spurious colocalization. Sentinel eQTL were defined across 174 published datasets (Supplementary Table 10), as described previously[41]. We did not use statistical approaches developed to distinguish colocalization from shared genetic effects because these have very limited resolution at high LD levels $(r^2 > 0.8)[42]$. Genetic risk score (GRS) analysis of COVID-19 hospitalization and severity First, in each study (AncestryDNA, GHS, UKB and PMBB), we created a GRS for each COVID-19 positive individual based on variants that were reported to associate with COVID-19

susceptibility in previous GWAS and that we (i) independently replicated; and (ii) found to be associated with COVID-19 severity. We used as weights the effect (beta) reported in previous GWAS (Supplementary Table 5). Second, we ranked COVID-19 individuals based on the GRS and created a new binary GRS predictor by assigning each individual to a high (top 5%) or low (rest of the population) percentile group. Third, for studies with >100 hospitalized cases, the we used logistic regression to test the association between the binary GRS predictor and risk of hospitalization (hospitalized cases vs. all other cases), including as covariates age, sex and ten ancestry-informative PCs. In addition to age and sex, we included as additional covariates established clinical risk factors for COVID-19 that were significantly associated in each respective study: BMI, smoking status, hypertension and chronic kidney disease for GHS; BMI, smoking status, hypertension and chronic obstructive pulmonary disease in Europeans of the UKB; hypertension, CKD, COPD, diabetes in AncestryDNA. We repeated the association analysis (i) using different percentile cut-offs for the GRS (5%, 10%, 20%, 30% and 40%); and (ii) to test the association with disease severity (severe cases vs. all other cases).

Results availability

All genotype-phenotype association results reported in this study are available for browsing using the RGC's COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use is limited to research purposes in accordance with the Terms of Use (https://rgc-covid19.regeneron.com/terms-of-use).

Competing interests

- 313 J.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., H.G., D.S., F.S.P.K., J.D.B., C.O.,
- 314 A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, M.J., S.B., W.J.S., A.R.S., A.E.L., J.M., J.O.,
- 315 L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of
- Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R., M.V.C., D.S.P., S.C.K.
- 317 A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current employees at
- 318 AncestryDNA and may hold equity in AncestryDNA. The other authors declare no competing
- 319 interests.

320

FIGURES




Figure 1. Comparison of effect sizes across COVID-19 susceptibility and severity outcomes for six previously reported (A, B) and three novel (C) risk variants.

(A, B) Six variants that were reported to associated with COVID-19 susceptibility in previous studies and replicated in our analysis. Of these, four variants also associated with disease severity among COVID-19 cases (in/near *LZTFL1*, *CCHCR1*, *DPP9* and *IFNAR2*; panel A), whereas two variants did not (in *ABO* and *SLC6A20*, panel B).

(C) Three novel risk variants for COVID-19 discovered in the trans-ancestry meta-analysis of risk of COVID-19 hospitalization across six studies (AncestryDNA, GHS, UKB, PMBB, Ellinghaus[19] et al. and Pairo-Castineira et al.[18]).




Figure 2. Summary of association results from the trans-ancestry meta-analysis of risk of COVID-19 hospitalization. The meta-analysis included results from six studies (AncestryDNA, GHS, UKB, PMBB, Ellinghaus et al. [19] and Pairo-Castineira et al. [18] and four ancestries (AFR, AMR, EUR and SAS), totaling 5,461 hospitalized cases and 661,632 controls with no record of SARS-CoV-2 infection.




Figure 3. Association between a four-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases of European ancestry.

(A) Association between high genetic risk and severe disease. Overall risk of severe disease is shown for individuals in the top GRS percentile, agnostic to the number of clinical risk factors present. The association was tested in two studies separately (AncestryDNA and UKB studies) using logistic regression, with established risk factors for COVID-19 included as covariates (see Methods for details). Results were then meta-analyzed across studies, for a combined sample size of 8,423 COVID-19 cases, including 744 with severe disease. N in red: number of COVID-19 cases in the top GRS percentile. N in grey: number of COVID-19 cases in the rest of population.

(B) Rate of severe disease in UK Biobank and AncestryDNA study, after stratifying by the number of clinical risk factors and genetic risk score. High genetic risk: top 10% of the GRS. Low genetic risk: bottom 90% of the GRS (*i.e.* all other COVID-19 cases).

(C) Association between high genetic risk (top 10% of GRS vs. all other COVID-19 cases) and severe disease, after stratifying by the number of pre-existing clinical risk factors. The association was tested in the UK Biobank and AncestryDNA studies, with results combined using inverse-variance meta-analysis.

TABLES

 Table 1. Top associations identified in the trans-ancestry meta-analysis of risk of COVID-19 hospitalization. The meta-analysis included results from six studies (AncestryDNA, GHS, UKB, PMBB, Pairo-Castineira et al.[18] and Ellinghaus et al. [19]) and four ancestries (AFR, AMR, EUR and SAS), totaling 5,461 hospitalized cases and 661,632 controls with no record of SARS-CoV-2 infection.

rsID	Position hg38	Effect allele	Odds ratio (LCI,UCI)	P-value	Effect allele frequency	N cases (N with 0 1 2 copies of the effect allele)	N controls (N with 0 1 2 copies of the effect allele)	Nearest gene
Previously reported associations								
rs73064425	3:45859597	T	1.716 (1.589, 1.854)	5.42E-43	0.074	5461 (4205 1165 87)	661632 (568579 88970 4081)	LZTFL1
rs143334143	6:31153649	A	1.335 (1.233, 1.447)	1.29E-12	0.072	5461 (4525 881 52)	661632 (569685 88265 3678)	CCHCR1
rs2277732	19:4723658	A	1.225 (1.166, 1.287)	8.40E-16	0.300	5461 (2371 2411 677)	661632 (325425 276058 60146)	DPP9
rs13050728	21:33242905	T	1.210 (1.153, 1.270)	1.24E-14	0.315	5461 (2237 2491 729)	661632 (311728 283741 66160)	IFNAR2
Novel associations								
rs79833209	5:163300447	T	1.544 (1.326, 1.796)	2.02E-08	0.022	5387 (5072 308 4)	652327 (624117 27910 296)	CCNG1
rs4782327	16:89117727	G	1.171 (1.110, 1.236)	8.15E-09	0.216	5461 (3109 2002 346)	661632 (407670 222489 31470)	ACSF3
rs12461764	19:51739497	G	1.181 (1.116, 1.250)	1.11E-08	0.346	3785 (1431 1770 582)	653252 (279857 295218 78176)	FPR1

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

SUPPLEMENTARY FIGURES Provided in a separate file. Supplementary Figure 1. Summary of association results from the meta-analysis of two phenotypes related to disease severity among COVID-19 cases. (A) Phenotype COVID-19 positive hospitalized (N=2,052) vs COVID-19 positive and not hospitalized (N=9,098). (B) Phenotype COVID-19 positive severe (N=815) vs COVID-19 positive and not hospitalized (N=8,999).Supplementary Figure 2. Three novel loci identified in the trans-ancestry meta-analysis of risk of COVID-19 hospitalization. (A) rs79833209 (5:163300447:C:T, effect allele C) in 5q34, near CCNG1. (B) rs4782327 (16:89117727:G:C, effect allele G) in 16q24.3 in ACSF3. (C) rs12461764 (19:51739497:G:T, effect allele G) in 19q13.41 near *FPR1*. RR: number of individuals homozygous for reference allele. RA: number of heterozygous individuals. RA: number of individuals homozygous for alternative (effect) allele. AAF: alternative allele frequency. OR: odds ratio. Supplementary Figure 3. Association between the continuous severity score and key individual measures of severity in the AncestryDNA study. The continuous severity score was derived from the first principal component across nine survey fields related to COVID-19 clinical outcomes, including three symptoms, hospitalization, ICU admittance, and other severe complications due to COVID-19 illness (Methods). Plots reflect mean symptom severity (top three panels) or incident prevalence (bottom three panels) for several fields as a function of ascending

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

severity decile. Symptom information was encoded as follows: 0=None, 0.2=Very Mild, 0.4=Mild, 0.6=Moderate, 0.8=Severe, and 1.0=Very Severe. A paucisymptomatic case corresponds to reporting symptoms of mild intensity or less for any of the symptom severity questions. Supplementary Figure 4. Association between a four-SNP genetic risk score (GRS) and risk of hospitalization among COVID-19 cases of European ancestry. (A) Association between high genetic risk and hospitalization. Overall risk of hospitalization is shown for individuals in the top GRS percentile, agnostic to the number of clinical risk factors present. The association was tested in three studies separately (AncestryDNA, GHS and UKB studies) using logistic regression, with established risk factors for COVID-19 included as covariates (see Methods for details). Results were then meta-analyzed across studies, for a combined sample size of 9,277 COVID-19 cases, including 1,832 who were hospitalized. N in red: number of COVID-19 cases in the top GRS percentile. N in grey: number of COVID-19 cases in the rest of population. (B) Rate of hospitalization in UK Biobank and Ancestry DNA study, after stratifying by the number of clinical risk factors and genetic risk score. High genetic risk: top 10% of the GRS. Low genetic risk: bottom 90% of the GRS (i.e. all other COVID-19 cases). (C) Association between high genetic risk (top 10% of GRS vs. all other COVID-19 cases) and hospitalization, after stratifying by the number of pre-existing clinical risk factors. The association was tested in the UK Biobank and AncestryDNA studies, with results combined using inversevariance meta-analysis.

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

SUPPLEMENTARY TABLES Provided in a separate file. Supplementary Table 1. Breakdown of COVID-19 status across the four studies included in the analysis. Supplementary Table 2. Demographics and clinical characteristics of study participants. Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed. Supplementary Table 4. Genomic inflation factor (lambda) across the seven COVID-19 phenotypes analyzed. Supplementary Table 5. Eight variants associated with COVID-19 susceptibility in previous **GWAS.** Supplementary Table 6. Association between eight published risk variants for COVID-19 and five disease susceptibility phenotypes in this study. P-values shown in red were significant after correcting for the 40 tests performed (P<0.00125). Supplementary Table 7. Comparison of effect sizes between ancestries for the six published risk variants that were validated in this study.

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

Supplementary Table 8. Association between a COVID-19 severity score and seven variants (four known, three novel) associated with both disease risk and severity. Supplementary Table 9. Missense or predicted loss-of-function variants in high linkage disequilibrium (LD, $r^2>0.95$) with sentinel GWAS variants. Supplementary Table 10. Published gene expression datasets used to identify sentinel expression quantitative trait loci (eQTL) that co-localized (LD $r^2>0.95$) with sentinel GWAS variants. Supplementary Table 11. Expression quantitative trait loci (eQTL) that co-localized (LD $r^2>0.95$) with sentinel GWAS variants. Supplementary Table 12. Association between a four-SNP genetic risk score (GRS) and risk of hospitalization among COVID-19 cases. Supplementary Table 13. Association between a four-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases. Supplementary Table 14. Association between a four-SNP genetic risk score (GRS) and risk of hospitalization and severe disease, after stratifying COVID-19 cases by the number of preexisting clinical risk factors for severe COVID-19.

458 References

- 460 1. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. New
- England Journal of Medicine, 2020. **382**(8): p. 727-733.
- 2. Coronaviridae Study Group of the International Committee on Taxonomy of, V., *The*
- species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV
- 464 and naming it SARS-CoV-2. Nat Microbiol, 2020. **5**(4): p. 536-544.
- 465 3. World Health Organization Coronavirus Disease Weekly Epidemiological Update. 2020;
- 466 Available from: https://covid19.who.int/.
- 467 4. Guan, W.J., et al., Clinical Characteristics of Coronavirus Disease 2019 in China. N
- 468 Engl J Med, 2020. **382**(18): p. 1708-1720.
- 469 5. Richardson, S., et al., Presenting Characteristics, Comorbidities, and Outcomes Among
- 470 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama, 2020.
- 471 **323**(20): p. 2052-2059.
- 472 6. Atkins, J.L., et al., *PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID*-
- 473 19 IN OLDER ADULTS IN THE UK BIOBANK COMMUNITY COHORT. medRxiv,
- 474 2020: p. 2020.05.06.20092700.
- 475 7. Zhou, F., et al., Clinical course and risk factors for mortality of adult inpatients with
- 476 *COVID-19 in Wuhan, China: a retrospective cohort study.* Lancet, 2020. **395**(10229): p.
- 477 1054-1062.
- 478 8. Cummings, M.J., et al., Epidemiology, clinical course, and outcomes of critically ill
- 479 *adults with COVID-19 in New York City: a prospective cohort study.* Lancet, 2020.
- 480 **395**(10239): p. 1763-1770.


- 481 9. Rochwerg, B., A living WHO guideline on drugs for covid-19. BMJ 2020;370:m3379
- 482 2020.
- 483 10. Group, R.C., et al., Dexamethasone in Hospitalized Patients with Covid-19 Preliminary
- 484 Report. N Engl J Med, 2020.
- 485 11. FDA, Investigational COVID-19 Convalescent Plasma. 2020.
- 486 12. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 –interim
- 487 *WHO SOLIDARITY trial results.* medRxiv 2020; Available from:
- 488 <u>https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1?ijkey=6ff7378035b5</u>
- 489 c9c24346a6b90cadb5e866a63f71&keytype2=tf ipsecsha.
- 490 13. Jackson, L.A., et al., An mRNA Vaccine against SARS-CoV-2 Preliminary Report. N
- 491 Engl J Med, 2020. **383**(20): p. 1920-1931.
- 492 14. Walsh, E.E., et al., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
- 493 Candidates. N Engl J Med, 2020.
- 494 15. Hansen, J., et al., Studies in humanized mice and convalescent humans yield a SARS-
- 495 *CoV-2 antibody cocktail.* Science, 2020. **369**(6506): p. 1010-1014.
- 496 16. Baum, A., et al., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid
- 497 mutational escape seen with individual antibodies. Science, 2020. **369**(6506): p. 1014-
- 498 1018.
- 499 17. Shelton, J., F., Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa Filshtein-
- Somnez, Daniella Coker, Antony Symons, Jorge Esparza-Gordillo, The 23andMe
- 501 COVID-19 Team, Stella Aslibekyan, Adam Auton, *Trans-ethnic analysis reveals genetic*
- and non-genetic associations with COVID-19 susceptibility and severity. 2020.


- 503 18. Pairo-Castineira, E., et al, ... The GenOMICC Investigators, The ISARIC4C
- Investigators, The Covid-19 Human Genetics Initiative, Xia Shen, Kathy Rowan, Angie
- Fawkes, Lee Murphy, Chris P Ponting, Albert Tenesa, Mark Caulfield, Richard
- Scott, Peter JM Openshaw, Malcolm G Semple, Veronique Vitart, James F Wilson,
- J Kenneth Baillie, Genetic mechanisms of critical illness in Covid-19. medRxiv, 2020: p.
- 508 2020.09.24.20200048.
- 509 19. Ellinghaus, D., et al., Genomewide Association Study of Severe Covid-19 with
- 510 Respiratory Failure. New England Journal of Medicine, 2020.
- 511 20. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host
- genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J
- 513 Hum Genet, 2020. **28**(6): p. 715-718.
- 514 21. Tervaniemi, M.H., et al., Intracellular signalling pathways and cytoskeletal functions
- converge on the psoriasis candidate gene CCHCR1 expressed at P-bodies and
- 516 *centrosomes.* BMC Genomics, 2018. **19**(1): p. 432.
- 517 22. Ling, Y.H., et al., CCHCR1 interacts with EDC4, suggesting its localization in P-bodies.
- 518 Exp Cell Res, 2014. **327**(1): p. 12-23.
- 519 23. Olejnik-Schmidt, A.K., et al., Search for cellular partners of human papillomavirus type
- 520 *16 E2 protein.* Arch Virol, 2008. **153**(5): p. 983-90.
- 521 24. Muller, M. and C. Demeret, CCHCR1 interacts specifically with the E2 protein of human
- papillomavirus type 16 on a surface overlapping BRD4 binding. PLoS One, 2014. 9(3):
- 523 p. e92581.
- 524 25. Matsuura, K., M. Isogawa, and Y. Tanaka, Host genetic variants influencing the clinical
- 525 course of hepatitis B virus infection. J Med Virol, 2016. **88**(3): p. 371-9.

- 526 26. Kim, Y.J., et al., A genome-wide association study identified new variants associated
- with the risk of chronic hepatitis B. Hum Mol Genet, 2013. 22(20): p. 4233-8.
- 528 27. Vuille-dit-Bille, R.N., et al., *Human intestine luminal ACE2 and amino acid transporter*
- *expression increased by ACE-inhibitors.* Amino Acids, 2015. **47**(4): p. 693-705.
- 530 28. Hadjadj, J., et al., Impaired type I interferon activity and inflammatory responses in
- *severe COVID-19 patients.* Science, 2020. **369**(6504): p. 718-724.
- 532 29. Hellman, U., et al., Presence of hyaluronan in lung alveoli in severe Covid-19: An
- opening for new treatment options? J Biol Chem, 2020. **295**(45): p. 15418-15422.
- 534 30. Kaber, G., et al., Hyaluronan is abundant in COVID-19 respiratory secretions. medRxiv,
- 535 2020.
- 536 31. Siiskonen, H., et al., Hyaluronan synthase 1: a mysterious enzyme with unexpected
- *functions.* Front Immunol, 2015. **6**: p. 43.
- 538 32. Bell, T.J., et al., *Defective lung function following influenza virus is due to prolonged*,
- 539 reversible hyaluronan synthesis. Matrix Biol, 2019. **80**: p. 14-28.
- 540 33. Cui, Z., et al., The Receptor for Hyaluronan-Mediated Motility (CD168) promotes
- inflammation and fibrosis after acute lung injury. Matrix Biol, 2019. **78-79**: p. 255-271.
- 542 34. Shi, Y., et al., COVID-19 infection: the perspectives on immune responses. Cell Death
- 543 Differ, 2020. **27**(5): p. 1451-1454.
- 544 35. How CDC Is Making COVID-19 Vaccine Recommendations. 2020 [cited 2020]
- December 2, 2020]; Available from: https://www.cdc.gov/coronavirus/2019-
- ncov/vaccines/recommendations-process.html.
- 36. Roberts, G.H.L., AncestryDNA COVID-19 Host Genetic Study Identifies Three Novel
- 548 *Loci.* medRxiv, 2020.


549 37. Knight, S.C., COVID-19 Susceptibility and Severity Risks in a Survey of Over 500,000 550 People. medRxiv, 2020. 551 38. Park, J., et al., A genome-first approach to aggregating rare genetic variants in LMNA 552 for association with electronic health record phenotypes. Genet Med, 2020. 22(1): p. 553 102-111. 554 39. Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. 555 Nature, 2018. **562**(7726): p. 203-209. 556 40. Mbatchou, J., et al., Computationally efficient whole genome regression for quantitative 557 and binary traits. bioRxiv, 2020: p. 2020.06.19.162354. 558 41. Ferreira, M.A., et al., Shared genetic origin of asthma, hay fever and eczema elucidates 559 allergic disease biology. Nat Genet, 2017. 49(12): p. 1752-1757. 560 42. Chun, S., et al., Limited statistical evidence for shared genetic effects of eQTLs and 561 autoimmune-disease-associated loci in three major immune-cell types. Nat Genet, 2017. 562 **49**(4): p. 600-605.

MAIN FIGURES





<u>Figure 2.</u> Summary of association results from the trans-ancestry meta-analysis of risk of COVID-19 hospitalization. The meta-analysis included results from six studies (AncestryDNA, GHS, UKB, PMBB, Ellinghaus et al. [19] and Pairo-Castineira et al. [18]) and four ancestries (AFR, AMR, EUR and SAS), totaling 5,461 hospitalized cases and 661,632 controls with no record of SARS-CoV-2 infection.



severe disease among COVID-19 cases of European ancestry.